Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.
Robertson, Jane D
Kell, W Jonathan
Burnett, Alan K
Ryder, W David J
Morgenstern, Godfrey R
Scarffe, J Howard
AffiliationDepartment of Haematological Oncology, Christie Hospital, Manchester M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractThe role of autologous peripheral blood stem cell transplantation (APBSCT) in acute myeloid leukaemia (AML) remains controversial. The current study evaluated the application of APBSCT in a large consecutive series of patients with untreated AML, and compared outcome with a predictive model based on MRC AML10 data. Of 148 evaluable patients, 118 patients entered complete remission (CR) after induction therapy comprising three cycles of daunorubicin, cytosine arabinoside and oral 6-thioguanine. Of these patients, 68 (57%) proceeded to consolidation therapy with two courses of intermediate dose cytosine arabinoside, and stem cell mobilisation, and 40 of these patients (34%) underwent the APBSCT procedure after high dose busulphan conditioning. Harvest quality was the main factor precluding APBSCT. Five-year event-free survival (EFS) in patients who achieved CR was 38% and in APBSCT patients was 57%. There were no transplant-related deaths. No significant differences were demonstrated between observed and expected outcomes at 1 and 2 years, based on the predictive model derived from the MRC AML10 study. These data therefore indicate that only a third of eligible adult patients will undergo APBSCT. However, the results demonstrate favourable survival in such patients, with no transplant-related mortality.
CitationAutologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort. 2003, 8 (2):83-90 Hematology
- Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
- Authors: Demirer T, Petersen FB, Bensinger WI, Appelbaum FR, Fefer A, Rowley S, Sanders J, Chauncey T, Storb R, Lilleby K, Buckner CD
- Issue date: 1996 Jul
- Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
- Authors: Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK
- Issue date: 1997 Apr 1
- Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
- Authors: Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S
- Issue date: 1999 Feb
- Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
- Authors: Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ
- Issue date: 1996 May 30
- Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
- Authors: Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, Isidori A, Tura S
- Issue date: 1999 Sep